From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disorders

AI Summary

Evidence is limited to case reports, observational studies and three small RCTs; efficacy remains unconfirmed.
Microdosing and escalating sequential protocols are experimental, lack standardised definitions and robust evidence, and remain preliminary.
Significant safety concerns include cardiotoxicity and QTc prolongation, narrow therapeutic margin and reported fatalities; clinical use not recommended without larger trials.

J Psychopharmacol. 2026 May 12:2698811261443674. doi: 10.1177/02698811261443674. Online ahead of print.

ABSTRACT

BACKGROUND: Preliminary evidence examining ibogaine in neuropsychiatric and substance use disorders is accumulating. As patient interest and off-label use grow, clinicians require an understanding of emerging dosing strategies, investigational protocols, and reported adverse effects to appropriately counsel patients and contextualize potential risks and benefits.

METHODS: Databases were searched for human studies of ibogaine, noribogaine, or 5-MeO-DMT with relevant clinical outcomes, prioritizing randomized controlled trials (RCTs), microdosing paradigms, and sequential protocols.

RESULTS: Only three RCTs were identified. First, a double-blind pilot study in 20 cocaine-dependent adults found that a single 1800 mg dose of ibogaine was associated with reduced craving versus placebo over follow-up of up to 24 weeks. Second, an ascending-dose trial in 36 healthy volunteers showed that noribogaine doses of 3-60 mg were safe and well-tolerated, without opioid-agonist effects. Third, a randomized crossover trial in 27 opioid-dependent patients receiving noribogaine 60-180 mg demonstrated dose-dependent heart rate-corrected QT interval (QTc) prolongation with non-significant reductions in withdrawal symptoms. Thus, two RCTs enrolled substance-dependent populations, while one focused on safety and pharmacokinetics in healthy volunteers. Microdosing and escalating sequential protocols remain experimental, lack standardized definitions, and are supported only by preliminary observational data. Adverse effects include neurologic, psychiatric, and cardiac events, including QTc prolongation; fatalities have occurred in the presence of medical and substance use comorbidities.

CONCLUSIONS: The available evidence is confined to case reports, observational analyses, and small early-phase or proof-of-concept studies. Given ibogaine’s cardiotoxicity and narrow therapeutic margin, clinical use cannot be recommended without confirmation from larger, well-controlled trials.

PMID:42117212 | DOI:10.1177/02698811261443674

Document this CPD